N. Farooqi

British Journal of Pharmacology · 2011

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from N. Farooqi's perspective

Ordered by how strongly the researchers N. Farooqi trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Multiple Sclerosis (Journal - Michigan State Medical Society)
  2. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. (American Journal of Pathology)
  3. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages (Nature Immunology)
  4. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (New England Journal of Medicine)
  5. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand (Nature Medicine)
  6. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (Annals of Neurology)
  7. A controlled trial of natalizumab for relapsing multiple sclerosis. (New England Journal of Medicine)
  8. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
  9. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins (Nature)
  10. IL-17 and Th17 Cells. (Annual Review of Immunology)

Their papers